568 related articles for article (PubMed ID: 26051506)
21. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study.
Laubach JP; Schjesvold F; Mariz M; Dimopoulos MA; Lech-Maranda E; Spicka I; Hungria VTM; Shelekhova T; Abdo A; Jacobasch L; Polprasert C; Hájek R; Illés Á; Wróbel T; Sureda A; Beksac M; Gonçalves IZ; Bladé J; Rajkumar SV; Chari A; Lonial S; Spencer A; Maison-Blanche P; Moreau P; San-Miguel JF; Richardson PG
Lancet Oncol; 2021 Jan; 22(1):142-154. PubMed ID: 33301738
[TBL] [Abstract][Full Text] [Related]
22. Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma.
Cheng T; Grasse L; Shah J; Chandra J
Drugs Today (Barc); 2015 Aug; 51(8):491-504. PubMed ID: 26380387
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
Wolf JL; Siegel D; Goldschmidt H; Hazell K; Bourquelot PM; Bengoudifa BR; Matous J; Vij R; de Magalhaes-Silverman M; Abonour R; Anderson KC; Lonial S
Leuk Lymphoma; 2012 Sep; 53(9):1820-3. PubMed ID: 22288662
[No Abstract] [Full Text] [Related]
24. Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat.
Afifi S; Michael A; Azimi M; Rodriguez M; Lendvai N; Landgren O
Pharmacotherapy; 2015 Dec; 35(12):1173-88. PubMed ID: 26684557
[TBL] [Abstract][Full Text] [Related]
25. Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma.
Suzuki K; Sunami K; Matsumoto M; Maki A; Shimada F; Suzuki K; Shimizu K
Acta Haematol; 2021; 144(3):264-274. PubMed ID: 33279887
[TBL] [Abstract][Full Text] [Related]
26. EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma.
Tzogani K; van Hennik P; Walsh I; De Graeff P; Folin A; Sjöberg J; Salmonson T; Bergh J; Laane E; Ludwig H; Gisselbrecht C; Pignatti F
Oncologist; 2018 May; 23(5):631-636. PubMed ID: 29192015
[TBL] [Abstract][Full Text] [Related]
27. Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.
San-Miguel JF; Hungria VTM; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Guenther A; Na Nakorn T; Siritanaratkul N; Schlossman RL; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Salwender H; Sopala M; Redhu S; Paul S; Corrado C; Richardson PG
Br J Haematol; 2017 Oct; 179(1):66-74. PubMed ID: 28653400
[TBL] [Abstract][Full Text] [Related]
28. A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.
Berenson JR; Hilger JD; Yellin O; Boccia RV; Matous J; Dressler K; Ghazal HH; Jamshed S; Kingsley EC; Harb WA; Noga SJ; Nassir Y; Swift RA; Vescio R
Ann Hematol; 2014 Jan; 93(1):89-98. PubMed ID: 24135804
[TBL] [Abstract][Full Text] [Related]
29. Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma.
Moore DC; Arnall JR; Harvey RD
J Oncol Pharm Pract; 2019 Apr; 25(3):613-622. PubMed ID: 30060709
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma.
Offidani M; Polloni C; Cavallo F; Liberati AM; Ballanti S; Pulini S; Catarini M; Alesiani F; Corvatta L; Gentili S; Caraffa P; Boccadoro M; Leoni P; Palumbo A
Leuk Lymphoma; 2012 Sep; 53(9):1722-7. PubMed ID: 22335534
[TBL] [Abstract][Full Text] [Related]
31. Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma.
Imai Y; Ohta E; Takeda S; Sunamura S; Ishibashi M; Tamura H; Wang YH; Deguchi A; Tanaka J; Maru Y; Motoji T
JCI Insight; 2016 Apr; 1(5):e85061. PubMed ID: 27699258
[TBL] [Abstract][Full Text] [Related]
32. Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.
Bloudek L; Roy A; Kish JK; Siegel DS; Jagannath S; Globe D; Orloski L; Kuriakose ET
J Manag Care Spec Pharm; 2016 Aug; 22(8):991-1002. PubMed ID: 27459662
[TBL] [Abstract][Full Text] [Related]
33. Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial.
Tan D; Phipps C; Hwang WY; Tan SY; Yeap CH; Chan YH; Tay K; Lim ST; Lee YS; Kumar SG; Ng SC; Fadilah S; Kim WS; Goh YT;
Lancet Haematol; 2015 Aug; 2(8):e326-33. PubMed ID: 26688485
[TBL] [Abstract][Full Text] [Related]
34. Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.
Vogl DT; Raje N; Jagannath S; Richardson P; Hari P; Orlowski R; Supko JG; Tamang D; Yang M; Jones SS; Wheeler C; Markelewicz RJ; Lonial S
Clin Cancer Res; 2017 Jul; 23(13):3307-3315. PubMed ID: 28053023
[No Abstract] [Full Text] [Related]
35. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.
Ocio EM; Vilanova D; Atadja P; Maiso P; Crusoe E; Fernández-Lázaro D; Garayoa M; San-Segundo L; Hernández-Iglesias T; de Alava E; Shao W; Yao YM; Pandiella A; San-Miguel JF
Haematologica; 2010 May; 95(5):794-803. PubMed ID: 19951978
[TBL] [Abstract][Full Text] [Related]
36. An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated Myeloma.
Hansen VL; Coleman M; Elkins S; Letzer JP; Levy MY; Seneviratne L; Rine J; White M; Kuriakose ET
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):400-407.e1. PubMed ID: 29656050
[TBL] [Abstract][Full Text] [Related]
37. Panobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma, candidates for autologous transplant.
Mangiacavalli S; Pochintesta L; Ravelli E; Baldini L; Ferretti VV; La Targia ML; Farina L; Cocito F; Cairoli R; Montefusco V; Corso A
Leuk Lymphoma; 2015 Jun; 56(6):1901-2. PubMed ID: 25347423
[No Abstract] [Full Text] [Related]
38. Panobinostat for the treatment of acute myelogenous leukemia.
Morabito F; Voso MT; Hohaus S; Gentile M; Vigna E; Recchia AG; Iovino L; Benedetti E; Lo-Coco F; Galimberti S
Expert Opin Investig Drugs; 2016 Sep; 25(9):1117-31. PubMed ID: 27485472
[TBL] [Abstract][Full Text] [Related]
39. Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data.
Majer I; van de Wetering G; Polanyi Z; Krishna A; Gray E; Roy A
Appl Health Econ Health Policy; 2017 Feb; 15(1):45-55. PubMed ID: 27550239
[TBL] [Abstract][Full Text] [Related]
40. The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells.
Chen G; Xu Z; Chang G; Hou J; Hu L; Zhang Y; Yu D; Li B; Chang S; Xie Y; Zhang Y; Wei R; Wu H; Xiao W; Sun X; Tao Y; Gao L; Dai B; Shi J; Zhu W
Oncol Rep; 2017 Jul; 38(1):488-496. PubMed ID: 28560392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]